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OBJECTIVES The aim of the present study was to determine the effect of angiotensin-converting enzyme
(ACE) inhibition on the local stimulated release of tissue plasminogen activator (t-PA) from
the endothelium.
BACKGROUND Angiotensin-converting enzyme inhibitor therapy may exert a beneficial effect on the
endogenous fibrinolytic balance.
METHODS Blood flow and plasma fibrinolytic factors were measured in both forearms of eight healthy
males who received unilateral brachial artery infusions of the endothelium-dependent
vasodilators substance P (2 to 8 pmol/min) and bradykinin (100 to 1,000 pmol/min), and the
endothelium-independent vasodilator sodium nitroprusside (2 to 8 g/min). These measure-
ments were performed on each of three occasions following one week of matched placebo,
quinapril 40 mg or losartan 50 mg daily administered in a double-blind randomized crossover
design.
RESULTS Sodium nitroprusside, substance P and bradykinin produced dose-dependent increases in the
blood flow of infused forearm (analysis of variance [ANOVA], p  0.001 for all). Although
sodium nitroprusside did not affect plasma t-PA concentrations, they were increased
dose-dependently in the infused forearm by substance P and bradykinin infusion (ANOVA,
p  0.001 for both). Bradykinin-induced release of active t-PA was more than doubled
during treatment with quinapril in comparison to placebo or losartan (two-way ANOVA: p
0.003 for treatment group, p  0.001 for t-PA response and p  ns for interaction), whereas
the substance P response was unaffected.
CONCLUSIONS We have shown a selective and marked augmentation of bradykinin-induced t-PA release
during ACE inhibition. These findings suggest that the beneficial clinical and vascular effects
of ACE inhibition may, in part, be mediated through local augmentation of bradykinin-
induced t-PA release. (J Am Coll Cardiol 2001;38:1402–8) © 2001 by the American
College of Cardiology
The fibrinolytic factor tissue plasminogen activator (t-PA)
is a serine protease that regulates the degradation of intra-
vascular fibrin and is released from the endothelium through
the translocation of a dynamic intracellular storage pool
(1,2). If endogenous fibrinolysis is to be effective then the
rapid mobilization of t-PA from the endothelium is essen-
tial, because thrombus dissolution is much more effective if
t-PA is incorporated during, rather than after, thrombus
formation (3). The efficacy of plasminogen activation and
fibrin degradation is further determined by the relative
balance between the acute local release of t-PA and its
subsequent inhibition through formation of complexes with
the serpin plasminogen activator inhibitor type 1 (PAI-1).
This dynamic aspect of endothelial function and fibrinolytic
balance may be directly relevant to the pathogenesis of
atherothrombosis, but only recently have robust methods to
determine acute t-PA release been developed (4–7).
Small areas of denudation and thrombus deposition are a
common finding on the surface of atheromatous plaques
(8,9) and are usually subclinical. However, in the presence of
an imbalance in the coagulation or fibrinolytic systems, such
microthrombi may propagate, ultimately leading to arterial
occlusion (10). Bradykinin is released during the contact
phase of coagulation, when high-molecular-weight kinino-
gen is cleaved by kallikrein to produce a disulphide-linked
light and heavy chain (11,12). Although an inflammatory
mediator, bradykinin is also a potent endothelial cell stim-
ulant that can induce the acute release of t-PA from the
endothelium (7,13) through a B2 receptor mechanism (14).
Thus, following activation of the intrinsic coagulation
pathway, the liberation of bradykinin may represent an
important negative feedback loop in which bradykinin-
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induced t-PA release inhibits thrombus formation within
the vascular lumen when localized endothelial denudation
occurs. Furthermore, given that bradykinin-induced fore-
arm vasodilatation is potentiated by angiotensin-converting
enzyme (ACE) inhibition (15), such actions may be en-
hanced in the presence of ACE inhibition and may, in part,
explain the anti-ischemic action of this therapy in vascular
disease (16). However, although inferred, the potentiation
of bradykinin-induced t-PA release by ACE inhibition has
yet to be established. Therefore, the aim of the present study
was to determine whether systemic ACE inhibition could
augment acute local t-PA release from the endothelium in
vivo in humans.
METHODS
Subjects. Eight healthy male nonsmokers, ages between 21
and 30 years, participated in the study, which was under-
taken with the approval of the local research ethics com-
mittee, in accordance with the Declaration of Helsinki and
with the written informed consent of each subject. Except
for study medication, none of the subjects received vasoac-
tive drugs in the week before each phase of the study, and all
abstained from alcohol for 24 h and from food and caffeine-
containing drinks for at least 4 h before each study. All
studies were carried out in a quiet, temperature-controlled
room maintained at 22°C to 24°C.
Measurements. FOREARM BLOOD FLOW AND HEMODY-
NAMICS. Blood flow was measured in both forearms by
venous occlusion plethysmography using mercury-in-silastic
strain gauges applied to the widest part of the forearm as
previously described (17). Analogue voltage output from an
EC-4 Strain Gauge Plethysmograph (D.E. Hokanson Inc.,
Bellevue, Washington) was processed by a MacLab
analogue-to-digital converter and Chart v3.3.8 software
(AD Instruments Ltd., Castle Hill, Australia) and recorded
onto a Macintosh Classic II computer (Apple Computers
Inc., Cupertino, California). Calibration was achieved using
the internal standard of the plethysmograph.
Blood pressure and heart rate were monitored in the
noninfused arm at intervals throughout each study using a
semiautomated noninvasive oscillometric sphygmomanom-
eter (Takeda UA 751, Takeda Medical Inc., Tokyo, Japan).
ASSAYS. Venous cannulae (17G) were inserted into large
subcutaneous veins of the antecubital fossa in both arms.
Ten to 20 ml of blood was withdrawn simultaneously from
each arm and collected into acidified buffered citrate
(Biopool Stabilyte, Umeå, Sweden, for t-PA assays), citrate
(Monovette, Sarstedt, Nu¨mbrecht, Germany, for PAI-1
assays) and lithium heparin (for ACE activity assays) tubes,
and kept on ice before being centrifuged at 2,000 g for
30 min at 4°C. Platelet-free plasma was decanted and stored
at 80°C before assay (18).
Plasma t-PA and PAI-1 antigen and activity concentra-
tions were determined using enzyme-linked immunosor-
bent assays and a photometric method as previously de-
scribed (5,19). Plasma ACE activity was determined using a
spectophotometric technique (Sigma Chemical Corpora-
tion, St. Louis, Missouri) (20). Hematocrit was determined
by capillary tube centrifugation of blood anticoagulated by
ethylene diamine tetraacetic acid.
Study design. Subjects attended on each of three study
days, two weeks apart, having received matched placebo,
quinapril 40 mg and losartan 50 mg (an angiotensin II type
1 (AT1) receptor antagonist) once daily for the seven days
before attendance. The subjects received each of the medi-
cations in a double-blind randomized crossover design. On
each study day, the final dose of placebo, quinapril or
losartan was taken at 08.00 hr. Six hours later, the subjects
rested recumbent, and strain gauges and cuffs were applied
to the forearms. The brachial artery of the nondominant
arm was cannulated with a 27-standard wire gauge steel
needle (Cooper’s Needle Works Ltd., Birmingham, United
Kingdom) under 1% lidocaine (Xylocaine: Astra Pharma-
ceutical Ltd., Kings Langley, United Kingdom) local anes-
thesia. The total rate of intra-arterial infusions was main-
tained constant at 1 ml/min and forearm blood flow was
measured every 10 min throughout all studies. Intrabrachial
infusions of substance P (Clinalfa AG, La¨ufelfingen, Swit-
zerland; endothelium-dependent vasodilator) at 2, 4 and
8 pmol/min (5,19), sodium nitroprusside (David Bull Lab-
oratories, Warwick, United Kingdom; endothelium-
independent vasodilator) at 2, 4 and 8 g/min (5,7) and
bradykinin (Clinalfa AG; endothelium-dependent vasodila-
tor) at 100, 300 and 1,000 pmol/min were given for 10 min
at each dose in that order. Saline was infused for 30 min
before the substance P, sodium nitroprusside and bradyki-
nin infusions.
Data analysis and statistics. Plethysmographic data were
extracted from the Chart data files. Forearm blood flows
were calculated for individual venous occlusion cuff infla-
tions by a template spreadsheet (Excel v5.0; Microsoft
Corporation, Cambridge, Massachusetts) as previously de-
scribed (5,7,19). Estimated net release of t-PA activity and
antigen was previously defined (5,7,19) as the product of the
infused forearm plasma flow (based on the mean hematocrit
and the infused forearm blood flow) and the concentration
difference between the infused and noninfused arms. Data
were examined, where appropriate, by analysis of variance
(ANOVA) with repeated measures and two-tailed paired
Student t test using Excel v5.0 (Microsoft). All results are
expressed as mean  standard error of the mean. Statistical
significance was taken at the 5% level.
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ANOVA  analysis of variance
AT1  angiotensin II type 1
PAI-1  plasminogen activator inhibitor type 1
t-PA  tissue plasminogen activator
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RESULTS
Oral and intra-arterial drug administrations were well tol-
erated without significant adverse effects. Consistent with
previous studies (7), transient patchy flushing and skin
edema of the infused arm occurred with bradykinin infusion
at doses300 pmol/min. There were no significant changes
in heart rate, blood pressure and noninfused forearm blood
flow (data on file) during or between study days. In
comparison to placebo and losartan, plasma ACE activity
was suppressed during quinapril administration (14.1 
0.8 IU/ml, 17.9  2.4 IU/ml and 7.6  1.6 IU/ml
respectively: p  0.004, ANOVA).
Forearm blood flow responses. Substance P, sodium ni-
troprusside and bradykinin produced dose-dependent fore-
arm vasodilatation during each study visit (one-way
ANOVA: p  0.001 for all) (Fig. 1). There were no
significant differences between the magnitude of the fore-
arm blood flow responses during placebo, quinapril or
losartan administration (two-way ANOVA: p  ns for
treatment group, p  0.001 for forearm blood flow re-
sponse, p  ns for interaction). There was a modest trend
for bradykinin-induced vasodilatation to be greater during
quinapril administration, but this was not statistically sig-
nificant (two-way ANOVA: p  0.12 for quinapril vs.
placebo, p  0.001 for forearm blood flow response, p  ns
for interaction).
Plasma fibrinolytic parameters. Substance P and bradyki-
nin caused dose-dependent increases in plasma t-PA anti-
gen and activity concentrations in the infused arm during
each study visit (one-way ANOVA: p  0.001 for all)
(Table 1). There was a modest but significant increase in
plasma t-PA concentrations in the noninfused arm during
infusion of bradykinin, but not substance P. Despite sub-
stantial increases in blood flow, sodium nitroprusside had no
effect on plasma t-PA concentrations in either arm. During
quinapril administration, there was a significant increase in
bradykinin, but not substance P, induced increases of
plasma t-PA antigen (two-way ANOVA: p  0.05 for
treatment group, p  0.001 for t-PA response, p  ns for
interaction) and activity (p  0.001 for treatment group,
p  0.001 for t-PA response, p  ns for interaction)
concentrations in the infused forearm (Table 1).
There were no significant differences in basal plasma
PAI-1 antigen concentrations during placebo, quinapril or
losartan administration, or stimulated release of PAI-1
during substance P, sodium nitroprusside or bradykinin
infusion (data on file).
Release of t-PA. Substance P and bradykinin caused dose-
dependent increases in the plasma t-PA antigen and activity
concentration differences between the forearms, and the
estimated net release of t-PA antigen and activity during
each study visit (one-way ANOVA: p  0.001 for all)
Figure 1. Infused forearm blood flow response to intrabrachial infusion of substance P, sodium nitroprusside and bradykinin during placebo (open circles),
quinapril (closed circles) and losartan (closed squares) administration. p  0.001 (analysis of variance) for all blood flow responses.
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Table 1. Effect of Placebo, Quinapril and Losartan on Plasma t-PA Antigen and Activity Concentrations in the Infused and Noninfused Forearms During Substance P, Sodium
Nitroprusside and Bradykinin Infusion
Substance P (pmol/min) Sodium Nitroprusside (g/min) Bradykinin (pmol/min)
0 2 4 8 0 2 4 8 0 100 300 1,000
Placebo
Plasma t-PA antigen (ng/ml)
Infused arm 3.9  0.8 4.8  0.8 5.8  0.7 7.5  1.1* 3.3  0.4 3.1  0.5 2.8  0.7 3.8  0.7 3.6  0.6 5.1  0.9 8.0  2.0 13.2  4.4*
Noninfused arm 4.0  0.9 5.3  1.5 4.1  0.8 4.6  1.0 3.9  0.8 3.7  0.8 3.8  0.7 3.4  0.6 3.3  0.5 3.8  1.2 4.2  1.1 6.0  2.3†
Plasma t-PA activity (IU/ml)
Infused arm 1.8  0.2 2.5  0.4 3.7  0.9 4.8  1.1* 1.9  0.4 1.5  0.1 1.5  0.1 1.6  0.2 1.5  0.2 2.5  0.3 4.5  0.9 8.5  2.0*
Noninfused arm 1.9  0.2 2.0  0.3 1.8  0.2 1.8  0.2 1.8  0.2 1.9  0.3 1.7  0.2 1.7  0.2 1.7  0.2 1.8  0.2 2.2  0.2 2.4  0.4†
Quinapril
Plasma t-PA antigen (ng/ml)
Infused arm 2.4  0.3 3.6  0.4 4.2  0.4 6.3  0.7* 3.0  0.3 3.0  0.4 2.6  0.3 2.9  0.5 3.2  0.4 8.0  0.8 11.7  1.7 19.6  6.5*§
Noninfused arm 3.2  0.3 3.3  0.3 3.4  0.4 3.7  0.5 3.0  0.1 2.8  0.3 3.0  0.2 2.9  0.1 2.9  0.1 4.4  0.6 6.2  1.6 10.0  4.3†
Plasma t-PA activity (IU/ml)
Infused arm 1.3  0.1 2.5  0.4 2.8  0.3 5.2  1.1* 1.6  0.2 1.5  0.1 1.5  0.1 1.5  0.1 1.4  0.1 6.1  1.1 8.9  1.8 12.7  1.9*‡
Noninfused arm 1.4  0.1 1.4  0.1 1.4  0.2 1.5  0.1 1.4  0.2 1.4  0.2 1.3  0.1 1.3  0.1 1.3  0.1 2.2  0.7 2.6  0.8 3.7  1.2†
Losartan
Plasma t-PA antigen (ng/ml)
Infused arm 3.4  0.3 4.4  0.7 6.3  1.6 7.6  1.3* 3.7  0.5 3.2  0.2 3.5  0.4 3.7  0.2 3.2  0.3 5.4  0.6 7.9  1.2 9.4  1.4*
Noninfused arm 3.3  0.3 3.6  0.4 3.8  0.4 4.9  0.6 3.6  0.3 3.2  0.3 3.4  0.3 3.2  0.2 3.2  0.3 3.5  0.3 4.0  0.5 4.7  0.6†
Plasma t-PA activity (IU/ml)
Infused arm 1.4  0.2 3.4  1.1 2.5  0.4 5.2  1.2* 1.6  0.1 1.5  0.1 1.4  0.1 1.4  0.1 1.5  0.1 3.3  0.4 5.3  0.7 7.4  1.4*
Noninfused arm 1.6  0.2 1.7  0.1 1.8  0.2 2.7  0.5 1.5  0.1 1.6  0.1 1.4  0.1 1.4  0.1 1.6  0.2 1.7  0.1 1.8  0.1 2.2  0.3†
*p  0.001; †p  0.05; ‡p  0.001; §p  0.05. One-way analysis of variance dose response; Two-way analysis of variance: quinapril versus losartan and placebo (p  0.001 for t-PA response and p  ns for interaction).















(Fig. 2). During quinapril administration, there was a
significant increase in bradykinin- but not substance
P-induced release of active t-PA (two-way ANOVA: p 
0.003 for treatment group, p  0.001 for t-PA response,
p ns for interaction) (Fig. 2) and a trend for t-PA antigen
(two-way ANOVA: p  0.09 for treatment group, p 
0.001 for t-PA response, p  ns for interaction) (Fig. 2).
Quinapril increased the area under the curve for the net
release of active t-PA by 135% and 125% in comparison to
placebo and losartan respectively.
DISCUSSION
For the first time, we have shown that in contrast to AT1
receptor antagonism, ACE inhibition potentiates bradykinin-
induced endogenous t-PA release from the endothelium.
However, this potentiation appears to be specific to brady-
kinin because ACE inhibition did not appear to influence
substance-P-induced t-PA release. These findings suggest
that the beneficial clinical and vascular effects of ACE
inhibition (16) may, in part, be mediated through the acute
local augmentation of bradykinin-induced t-PA release.
Endogenous fibrinolysis and acute coronary syndromes.
The endogenous fibrinolytic system can have important
clinical effects, as exemplified by the observation that in a
third of patients with an acute myocardial infarction, the
infarct-related artery spontaneously reperfuses within 12 h
(21–23). Moreover, a low fibrinolytic activity is associated
with an increased risk of myocardial infarction in young
Figure 2. Forearm concentration difference (left) and estimated net release (right) of tissue plasminogen activator (t-PA) antigen (upper, solid lines) and
activity (lower, dashed lines) in response to intrabrachial infusion of bradykinin during placebo (open circles), quinapril (closed circles) and losartan
(closed squares) administration. p  0.001 (analysis of variance, ANOVA) for all responses. *p  0.003, †p  0.03, ‡p  0.09, §p  0.13 two-way
ANOVA: quinapril versus losartan and placebo (p  0.001 for t-PA response and p  ns for interaction).
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men (24) and predicts which patients with unstable angina
will develop myocardial infarction (25). Clinical studies of
patients with unstable angina have also indicated that there
is enhanced activation of the kallikrein system and that
bradykinin release is increased (26). Given this augmenta-
tion of bradykinin generation and the activation of the
intrinsic coagulation pathway in acute coronary syndromes,
ACE inhibition may have major beneficial effects on the
acute local fibrinolytic balance by markedly enhancing
bradykinin-induced t-PA release in areas of intravascular
thrombus formation.
ACE inhibition, bradykinin metabolism and t-PA re-
lease. More than 95% of bradykinin metabolism occurs
through ACE, whereas plasma substance P is metabolized
by several additional enzymes including dipeptidyl(amino)-
peptidase IV and aminopeptidase M (27). Moreover, the
tissue and cellular metabolism of substance P is performed
almost exclusively by neutral endopeptidase 24.11 (27).
Consistent with this, and with previous work in the forearm
circulation (28), we did not detect a significant influence of
ACE inhibition on substance-P-induced vasodilatation.
Indeed, ACE inhibition did not appear to influence
substance-P-induced t-PA release. This indicates that the
augmentation of bradykinin-induced t-PA release reflects
the inhibition of bradykinin metabolism rather than a
general enhancement of the capacity of the endothelium to
release t-PA acutely. Given the recent report (29) of even
greater reductions in cardiovascular events with omapatrilat,
a combined ACE and neutral endopeptidase inhibitor, the
potentiation of bradykinin-induced t-PA release may be
enhanced even further by such compounds. This requires
further investigation.
In contrast to the marked potentiation of t-PA release,
we failed to detect a significant increase in bradykinin-
induced vasodilatation during ACE inhibition. Benjamin et
al. (15) have previously reported that local ACE inhibition
causes a potentiation of the increases in blood flow associ-
ated with bradykinin infusion in the human forearm.
However, there did appear to be a trend toward an enhanced
blood flow response, and it is likely that our study lacked
sufficient power to detect this difference. This would also
suggest that, in comparison to vasomotor responses, ACE
inhibition has a proportionately greater effect on the en-
hancement of bradykinin-induced t-PA release given more
than a doubling of the release of active t-PA. In addition, it
is unlikely that the augmentation of active t-PA release by
ACE inhibition is due to the potentially greater increase in
blood flow because vasodilatation and increased blood flow
do not appear, by themselves, to cause t-PA release, as
demonstrated by the absence of an effect with sodium
nitroprusside infusion. This latter observation is in agree-
ment with our previous studies (5) and work by other groups
(4,6).
Conclusions. We have demonstrated a specific augmenta-
tion of bradykinin-induced t-PA release by ACE inhibition.
This effect appears to be independent of angiotensin II
action because AT1 receptor antagonism did not influence
the acute release of t-PA. These findings suggest that the
beneficial clinical and vascular effects of ACE inhibition
may, in part, be mediated through the acute local augmen-
tation of bradykinin-induced t-PA release.
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